Juno Therapeutics (JUNO) Reports In-Line Q1 EPS

Juno Therapeutics (NASDAQ: JUNO) reported Q1 EPS of ($0.71), in-line with the analyst estimate of ($0.71). Revenue for the quarter came in at $19.3 million versus the consensus estimate of $13.47 million.

Cash, cash equivalents, and marketable securities as of March 31, 2017 were $850.7 million compared to $922.3 million as of December 31, 2016.

"In the first quarter 2017, we made significant progress with our lead program, JCAR017, and we look forward to presenting updated data in DLBCL at ASCO,\" said Hans Bishop, Juno’s President and Chief Executive Officer. \"We also continue to advance our pipeline more broadly with eleven product candidates now in human testing. Already this year, we have initiated a number of trials, including a BCMA CAR T, a CD19-directed 4-1BBL armored CAR, a fully-human CD19 CAR T, a combination trial with JCAR014 and durvalumab, and a combination trial with JCAR014 and ibrutinib. With up to 20 ongoing trials by year end, we expect to gain additional insights that may lead to product candidates that can deliver long-term durable remissions for patients in need.”

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c
• Canterbury Park (CPHC) Misses Q2 EPS by 3c